Predictive Impact of Prognostic Nutritional Index in Patients with Cancer Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

References

• Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–742. https://e-century.us/files/ajcr/10/3/ajcr0108072.pdf
   PubMed Web of Science ®Google Scholar
• Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. Pd-L1. J Clin Pathol. 2018;71(3):189–194. doi: 10.1136/jclinpath-2017-204853.
   PubMed Web of Science ®Google Scholar
• Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, Wu K. Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 2018;17(1):129. doi: 10.1186/s12943-018-0864-3.
   PubMed Web of Science ®Google Scholar
• Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553(7686):91–95. doi: 10.1038/nature25015.
   PubMed Web of Science ®Google Scholar
• Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915–919. doi: 10.1158/2159-8290.CD-15-0563.
   PubMed Web of Science ®Google Scholar
• Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, Liu K, Guo W. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol. 2018;11(1):16. doi: 10.1186/s13045-018-0560-1.
   PubMedGoogle Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi: 10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–1030. doi: 10.1200/JCO.2013.53.0105.
   PubMed Web of Science ®Google Scholar
• Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125(9):3335–3337. doi: 10.1172/JCI83871.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–287. doi: 10.1038/nrc.2016.36.
   PubMed Web of Science ®Google Scholar
• Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–1492. doi: 10.1016/S1470-2045(17)30616-2.
   PubMed Web of Science ®Google Scholar
• Yamazaki N, Takenouchi T, Fujimoto M, Ihn H, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, et al. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemother Pharmacol. 2017;79(4):651–660. doi: 10.1007/s00280-016-3237-x.
   PubMed Web of Science ®Google Scholar
• Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol. 2017;35(14):1542–1549. doi: 10.1200/JCO.2016.70.1524.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A, et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in checkMate 227. J Clin Oncol. 2023;41(6):1200–1212. doi: 10.1200/JCO.22.01503.
   PubMed Web of Science ®Google Scholar
• Li Y, Ma Y, Wu Z, Zeng F, Song B, Zhang Y, Li J, Lui S, Wu M. Tumor mutational burden predicting the efficacy of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis. Front Immunol. 2021;12:751407. doi: 10.3389/fimmu.2021.751407.
   PubMed Web of Science ®Google Scholar
• Lee M, Samstein RM, Valero C, Chan TA, Morris LGT. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. Hum Vaccin Immunother. 2020;16(1):112–115. doi: 10.1080/21645515.2019.1631136.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463–1469. doi: 10.1126/science.aaf1490.
   PubMed Web of Science ®Google Scholar
• Huo G, Liu W, Chen P. Inhibitors of PD-1 in non-small cell lung cancer: a meta-analysis of clinical and molecular features. Front Immunol. 2022;13:875093. doi: 10.3389/fimmu.2022.875093.
   PubMedGoogle Scholar
• Yin L, Song C, Cui J, Wang N, Fan Y, Lin X, Zhang L, Zhang M, Wang C, Liang T, et al. Low fat mass index outperforms handgrip weakness and GLIM-defined malnutrition in predicting cancer survival: derivation of cutoff values and joint analysis in an observational cohort. Clin Nutr. 2022;41(1):153–164. doi: 10.1016/j.clnu.2021.11.026.
   PubMed Web of Science ®Google Scholar
• Bullock AF, Greenley SL, McKenzie GAG, Paton LW, Johnson MJ. Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis. Eur J Clin Nutr. 2020;74(11):1519–1535. doi: 10.1038/s41430-020-0629-0.
   PubMed Web of Science ®Google Scholar
• Naik GS, Waikar SS, Johnson AEW, Buchbinder EI, Haq R, Hodi FS, Schoenfeld JD, Ott PA. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer. 2019;7(1):89.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Marino P, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer. 2019;7(1):57.
   PubMed Web of Science ®Google Scholar
• Akce M, Liu Y, Zakka K, Martini DJ, Draper A, Alese OB, Shaib WL, Wu C, Wedd JP, Sellers MT, et al. Impact of sarcopenia, BMI, and inflammatory biomarkers on survival in advanced hepatocellular carcinoma treated with anti-PD-1 antibody. Am J Clin Oncol. 2021;44(2):74–81. doi: 10.1097/COC.0000000000000787.
   PubMed Web of Science ®Google Scholar
• Li P, Lai Y, Tian L, Zhou Q. The prognostic value of prognostic nutritional index in advanced cancer receiving PD-1/L1 inhibitors: a meta-analysis. Cancer Med. 2022;11:3048–3056. doi: 10.1002/cam4.4668.
   PubMed Web of Science ®Google Scholar
• Ni L, Huang J, Ding J, Kou J, Shao T, Li J, Gao L, Zheng W, Wu Z. Prognostic nutritional index predicts response and prognosis in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Nutr. 2022;9:823087. doi: 10.3389/fnut.2022.823087.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Yamada T, Komori K, Hara K, Kano K, Takahashi K, Kumazu Y, Fujikawa H, Numata M, Aoyama T, et al. Effect of prognostic nutrition index in gastric or gastro-oesophageal junction cancer patients undergoing nivolumab monotherapy. In Vivo. 2021;35(1):563–569. doi: 10.21873/invivo.12292.
   PubMed Web of Science ®Google Scholar
• Mei J, Sun XQ, Lin WP, Li SH, Lu LH, Zou JW, Wei W, Guo RP. Comparison of the prognostic value of inflammation-based scores in patients with hepatocellular carcinoma after anti-PD-1 therapy. J Inflamm Res. 2021;14:3879–3890. 10.2147/JIR.S325600
   PubMed Web of Science ®Google Scholar
• Peng L, Wang Y, Liu F, Qiu X, Zhang X, Fang C, Qian X, Li Y. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother. 2020;69(9):1813–1822. doi: 10.1007/s00262-020-02585-w.
   PubMed Web of Science ®Google Scholar
• Guller M, Herberg M, Amin N, Alkhatib H, Maroun C, Wu E, Allen H, Zheng Y, Gourin C, Vosler P, et al. Nutritional status as a predictive biomarker for immunotherapy outcomes in advanced head and neck cancer. Cancers (Basel). 2021;13(22):5772. doi: 10.3390/cancers13225772. 10.3390/cancers13225772
   PubMed Web of Science ®Google Scholar
• Liu N, Jiang A, Zheng X, Fu X, Zheng H, Gao H, Wang J, Liang X, Tian T, Ruan Z, et al. Prognostic nutritional index identifies risk of early progression and survival outcomes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors. J Cancer. 2021;12(10):2960–2967. doi: 10.7150/jca.55936.
   PubMed Web of Science ®Google Scholar
• Matsubara T, Takamori S, Haratake N, Toyozawa R, Miura N, Shimokawa M, Yamaguchi M, Seto T, Takenoyama M. The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab. J Thorac Dis. 2020;12(4):1520–1528. doi: 10.21037/jtd.2020.02.27.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Miyake M, Hori S, Ichikawa K, Omori C, Iemura Y, Owari T, Itami Y, Nakai Y, Anai S, et al. Clinical impact of sarcopenia and inflammatory/nutritional markers in patients with unresectable metastatic urothelial carcinoma treated with pembrolizumab. Diagnostics (Basel). 2020;10(5):310. doi: 10.3390/diagnostics10050310. 10.3390/diagnostics10050310
   PubMedGoogle Scholar
• Namikawa T, Yokota K, Tanioka N, Fukudome I, Iwabu J, Munekage M, Uemura S, Maeda H, Kitagawa H, Kobayashi M, et al. Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer. Surg Today. 2020;50(11):1486–1495. doi: 10.1007/s00595-020-02048-w.
   PubMed Web of Science ®Google Scholar
• Qi WX, Xiang Y, Zhao S, Chen J. Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab. Cancer Immunol Immunother. 2021;70(11):3199–3206. doi: 10.1007/s00262-021-02926-3.
   PubMed Web of Science ®Google Scholar
• Ishiyama Y, Kondo T, Nemoto Y, Kobari Y, Ishihara H, Tachibana H, Yoshida K, Hashimoto Y, Takagi T, Iizuka J, et al. Predictive impact of prognostic nutritional index on pembrolizumab for metastatic urothelial carcinoma resistant to platinum-based chemotherapy. Anticancer Res. 2021;41(3):1607–1614. doi: 10.21873/anticanres.14922.
   PubMed Web of Science ®Google Scholar
• Mirili C, Paydaş S, Ogul A, Gokcay S, Buyuksimsek M, Yetisir AE, Tohumcuoglu M, Karaalioglu B. Dynamic prognostic nutritional index could be a novel predictor of survival in lung cancer patients treated with nivolumab. Ann Clin Anal Med. 2019;11(3):186–190.
   Google Scholar
• Kim JH, Ahn B, Hong SM, Jung HY, Kim DH, Choi KD, Ahn JY, Lee JH, Na HK, Kim JH, et al. Real-world efficacy data and predictive clinical parameters for treatment outcomes in advanced esophageal squamous cell carcinoma treated with immune checkpoint inhibitors. Cancer Res Treat. 2022;54(2):505–516. doi: 10.4143/crt.2020.1198. 10.4143/crt.2020.1198
   PubMed Web of Science ®Google Scholar
• Lee J, Choi SH, Baek JH, Baek DW, Kim JG, Kang BW. Clinical impact of prognostic nutrition index for advanced gastric cancer patients with peritoneal metastases treated nivolumab monotherapy. Chonnam Med J. 2022;58(1):24–28. doi: 10.4068/cmj.2022.58.1.24.
   PubMedGoogle Scholar
• Booka E, Kikuchi H, Haneda R, Soneda W, Kawata S, Murakami T, Matsumoto T, Hiramatsu Y, Takeuchi H. Neutrophil-to-lymphocyte ratio to predict the efficacy of immune checkpoint inhibitor in upper gastrointestinal cancer. Anticancer Res. 2022;42(6):2977–2987. doi: 10.21873/anticanres.15781.
   PubMed Web of Science ®Google Scholar
• Araki T, Tateishi K, Komatsu M, Sonehara K, Wasamoto S, Koyama S, Yoshiike F, Hama M, Nishie K, Kondo D, et al. Predictive value of post-treatment c-reactive protein-to-albumin ratio in locally advanced non–small cell lung cancer patients receiving durvalumab after chemoradiotherapy. Thoracic Cancer. 2022;13(14):2031–2040. doi: 10.1111/1759-7714.14484. 10.1111/1759-7714.14484
   PubMed Web of Science ®Google Scholar
• Tanaka S, Uchino J, Yokoi T, Kijima T, Goto Y, Suga Y, Katayama Y, Nakamura R, Morimoto K, Nakao A, et al. Prognostic nutritional index and lung immune prognostic index as prognostic predictors for combination therapies of immune checkpoint inhibitors and cytotoxic anticancer chemotherapy for patients with advanced non-small cell lung cancer. Diagnostics (Basel). 2022;12(2):423. doi: 10.3390/diagnostics12020423. 10.3390/diagnostics12020423
   PubMedGoogle Scholar
• Zhang Y, Jin J, Tang M, Li P, Zhou LN, Du YP, Chen MB. Prognostic nutritional index predicts outcome of PD-L1 negative and MSS advanced cancer treated with PD-1 inhibitors. Biomed Res Int. 2022;2022:6743126. doi: 10.1155/2022/6743126.
   PubMed Web of Science ®Google Scholar
• Shoji F, Takeoka H, Kozuma Y, Toyokawa G, Yamazaki K, Ichiki M, Takeo S. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer. 2019;136:45–51. doi: 10.1016/j.lungcan.2019.08.006.
   PubMed Web of Science ®Google Scholar
• Zaitsu J, Yamashita Y, Ishikawa A, Saito A, Kagimoto A, Mimura T, Hirakawa T, Mito M, Fukuhara K, Senoo T, et al. Systemic inflammatory score predicts response and prognosis in patients with lung cancer treated with immunotherapy. Anticancer Res. 2021;41(7):3673–3682. doi: 10.21873/anticanres.15158.
   PubMed Web of Science ®Google Scholar
• Guven DC, Aktepe OH, Taban H, Aktas BY, Guner G, Yildirim HC, Sahin TK, Aksun MS, Dizdar O, Aksoy S, et al. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune checkpoint inhibitors. Biomark Med. 2021;15(13):1123–1130. doi: 10.2217/bmm-2020-0674.
   PubMed Web of Science ®Google Scholar
• Ogura Y, Kataoka N, Kunimatsu Y, Tachibana Y, Sugimoto T, Tani N, Sato I, Hirose K, Kato D, Takeda T, et al. Predictors of survival among Japanese patients receiving first-line chemoimmunotherapy for advanced non-small cell lung cancer. Thorac Cancer. 2021;12(1):97–105. doi: 10.1111/1759-7714.13720.
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu X, Liu J, Zhang D, Liu X, Yue Y, Zhou Q, Gao X, Chen M, Xu Y, et al. Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments. Transl Lung Cancer Res. 2021;10(12):4477–4493. doi: 10.21037/tlcr-21-710.
   PubMed Web of Science ®Google Scholar
• Stares M, Ding TE, Stratton C, Thomson F, Baxter M, Cagney H, Cumming K, Swan A, Ross F, Barrie C, et al. Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer. ESMO Open. 2022;7(2):100445. doi: 10.1016/j.esmoop.2022.100445.
   PubMed Web of Science ®Google Scholar
• Jain P, Jain C, Velcheti V. Role of immune-checkpoint inhibitors in lung cancer. Ther Adv Respir Dis. 2018;12:1753465817750075. doi: 10.1177/1753465817750075.
   Web of Science ®Google Scholar
• Evans DC, Corkins MR, Malone A, Miller S, Mogensen KM, Guenter P, Jensen GL, ASPEN Malnutrition Committee. The use of visceral proteins as nutrition markers: an ASPEN position paper. Nutr Clin Pract. 2021;36(1):22–28. doi: 10.1002/ncp.10588.
   PubMed Web of Science ®Google Scholar
• Gama-Axelsson T, Heimbürger O, Stenvinkel P, Bárány P, Lindholm B, Qureshi AR. Serum albumin as predictor of nutritional status in patients with ESRD. Clin J Am Soc Nephrol. 2012;7(9):1446–1453. doi: 10.2215/CJN.10251011.
   PubMed Web of Science ®Google Scholar
• Sadakane-Sakuramoto A, Hasegawa Y, Sugahara K, Horii N, Saito S, Nakao Y, Nanto T, Ono T, Domen K, Kishimoto H, et al. Change in nutritional status and dysphagia after resection of head and neck cancer. Nutrients. 2021;13(7):2438. doi: 10.3390/nu13072438. 10.3390/nu13072438
   PubMed Web of Science ®Google Scholar
• Ryan AM, Power DG, Daly L, Cushen SJ, Ní Bhuachalla Ē, Prado CM. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc. 2016;75(2):199–211. doi: 10.1017/S002966511500419X.
   PubMed Web of Science ®Google Scholar
• Pressoir M, Desné S, Berchery D, Rossignol G, Poiree B, Meslier M, Traversier S, Vittot M, Simon M, Gekiere JP, et al. Prevalence, risk factors and clinical implications of malnutrition in French comprehensive cancer centres. Br J Cancer. 2010;102(6):966–971. doi: 10.1038/sj.bjc.6605578.
   PubMed Web of Science ®Google Scholar
• Maasberg S, Knappe-Drzikova B, Vonderbeck D, Jann H, Weylandt KH, Grieser C, Pascher A, Schefold JC, Pavel M, Wiedenmann B, et al. Malnutrition predicts clinical outcome in patients with neuroendocrine neoplasia. Neuroendocrinology. 2017;104(1):11–25. doi: 10.1159/000442983.
   PubMed Web of Science ®Google Scholar
• Aaldriks AA, van der Geest LGM, Giltay EJ, Le Cessie S, Portielje JEA, Tanis BC, Nortier JWR, Maartense E. Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy. J Geriatr Oncol. 2013;4(3):218–226. doi: 10.1016/j.jgo.2013.04.001.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, et al. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events. Eur J Cancer. 2020;128:17–26. doi: 10.1016/j.ejca.2019.12.031.
   PubMed Web of Science ®Google Scholar
• Kalafati L, Mitroulis I, Verginis P, Chavakis T, Kourtzelis I. Neutrophils as orchestrators in tumor development and metastasis formation. Front Oncol. 2020;10:581457. doi: 10.3389/fonc.2020.581457.
   PubMed Web of Science ®Google Scholar
• Ruffell B, DeNardo DG, Affara NI, Coussens LM. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 2010;21(1):3–10. doi: 10.1016/j.cytogfr.2009.11.002.
   PubMed Web of Science ®Google Scholar
• Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45–56. doi: 10.1038/s41586-019-1593-5.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Park YS, Lee HW, Park TY, Lee JK, Heo EY. Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer. Sci Rep. 2022;12(1):626. doi: 10.1038/s41598-021-04630-9.
   PubMed Web of Science ®Google Scholar
• Guven DC, Sahin TK, Erul E, Cakir IY, Ucgul E, Yildirim HC, Aktepe OH, Erman M, Kilickap S, Aksoy S, et al. The association between early changes in neutrophil-lymphocyte ratio and survival in patients treated with immunotherapy. J Clin Med. 2022;11(15):4523. doi: 10.3390/jcm11154523.
   PubMed Web of Science ®Google Scholar
• Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345–359. doi: 10.1038/s41568-021-00347-z.
   PubMed Web of Science ®Google Scholar
• Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, et al. Systemic immunity is required for effective cancer immunotherapy. Cell. 2017;168(3):487–502 e15. doi: 10.1016/j.cell.2016.12.022.
   PubMed Web of Science ®Google Scholar
• Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60–65. doi: 10.1038/nature22079.
   PubMed Web of Science ®Google Scholar
• Hill M, Segovia M, Russo S, Girotti MR, Rabinovich GA. The paradoxical roles of inflammation during PD-1 blockade in cancer. Trends Immunol. 2020;41(11):982–993. doi: 10.1016/j.it.2020.09.003. 10.1016/j.it.2020.09.003
   PubMed Web of Science ®Google Scholar
• Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Quezada SA, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162(6):1257–1270. doi: 10.1016/j.cell.2015.08.015.
   PubMed Web of Science ®Google Scholar
• Yang W, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X, Meng X, Li L, Wang J, Xu C, et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature. 2016;531(7596):651–655. doi: 10.1038/nature17412.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22(8):1865–1874. doi: 10.1158/1078-0432.CCR-15-1507.
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572. doi: 10.1038/nri.2017.49.
   PubMed Web of Science ®Google Scholar
• Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, Osokin N, Kozlov I, Frenkel F, Gancharova O, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39(6):845–65 e7. doi: 10.1016/j.ccell.2021.04.014.
   PubMed Web of Science ®Google Scholar
• Dougan M, Luoma AM, Dougan SK, Wucherpfennig KW. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 2021;184(6):1575–1588. doi: 10.1016/j.cell.2021.02.011.
   PubMed Web of Science ®Google Scholar